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Abstract Diabetic macular edema remains a major
cause of visual impairment in adults despite the use of
intensive glycemic control, photocoagulation therapy
and new intravitreal drugs in the treatment of this
disease. Although early diagnosis and treatment lead
to better results, we still have patients who become
legally blind. Therefore, better structural and func-
tional characterization of this disease is necessary in
order to customize treatment.
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Introduction
Diabetic macular edema (DME) is the leading cause of
legal blindness in diabetic patients [1]. DME can occur
at any stage of diabetic retinopathy (DR), although it is
more likely to occur as the disease progresses [2]. The
pathophysiological mechanisms leading to DME are
still poorly understood due to its complex and
multifactorial origin. It is generally believed that
vascular microangiopathy, with endothelial cell dam-
age, pericyte loss and consecutive break-down of the
inner blood–retinal barrier, is involved in the patho-
genesis of DME [3, 4]. Moreover, other factors such as
hypoxia, altered blood flow, retinal ischemia, and
inflammation are also associated with the progression
of DME [5]. However, recently an increasing body of
evidence suggests that neurodegeneration precedes the
earliest clinical manifestation of diabetic retinal
vasculopathy [6, 7]. In fact, early clinical changes in
visual function have been found by means of colour
contrast sensitivity, dark adaptation (nyctometry),
electroretinography, and more recently by microperi-
metry, confirming the precocious occurrence of neu-
rovisual abnormalities in diabetic patients [8–11].
DME is currently evaluated with biomicroscopy,
color fundus photography, optical coherence tomog-
raphy (OCT), fluorescein angiography (FA) as mor-
phologic tests and visual acuity (VA) as a functional
test. FA has been used for more than 50 years in the
evaluation of external and internal blood–retinal
barriers. In DME, it has been mostly used for the
evaluation of unexplained visual loss and for guiding
treatment of clinically significant macular edema
(CSME) [12]. El Asrar et al. [13] showed that FA
may be particularly useful in detecting refractory areas
in previously treated DME cases with laser photoco-
agulation. However, FA is an invasive test and its use
in the management of DME is more limited than in the
past, even though it is mandatory before deciding any
therapeutic intervention [14].
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Recently, OCT has been proposed as a new
standard diagnostic technique to quantify and monitor
DME [15]. Browning et al. [16] demonstrated that
foveal and macular OCT thickness appear to be more
sensitive than slit lamp biomicroscopy in evaluating
CSME. Virgili et al. [17] reported high sensitivity and
specificity of OCT versus slit lamp biomicroscopy and
stereoscopic fundus photography in evaluating CSME,
especially in the initial stages. OCT allows for both
quantitative and qualitative evaluation of DME. Otani
et al. [18] described different OCT patterns of DME:
cystoid, sponge-like and subfoveal neuoretinal detach-
ment (SND). Several studies have shown a high
correlation between OCT findings and FA patterns in
DME [14, 19, 20]. These correlations address the
changes in intraretinal structure. In fact, large foveal
cysts, located in the outer nuclear layer and/or Henle’s
layer found on OCT correspond quite well to petaloid
cystoid leakage pattern on FA [19, 20]. Whereas FA
does not allow for SND visualization, OCT nicely
shows the extent and height of SND. Since OCT
introduction into clinical practice, prevalence and
prognosis of SND in diabetics have been more studied
and understood [21].
OCT also offers a repeatable and objective way to
evaluate retinal thickness and volume in DME, which
is the most used parameter in clinical trials when
evaluating the effect of any treatment [22]. With the
advent of spectral domain OCT (SD-OCT), fine
intraretinal structure can be analyzed in more detail.
In particular, the integrity of single retinal layers and
cyst localization within retinal layers can be precisely
determined. Moreover, the reflectivity of retinal cysts
was proposed as an indicator of exudative origin (high
internal reflectivity) versus degenerative origin (low
internal reflectivity) [23]. This parameter might be
important in treatment evaluation [23]. When evalu-
ating DME, we should bear in mind that the same OCT
machine should be used for the follow-up of any
individual eye in order to compare retinal thickness
values; otherwise a conversion factor for different
instruments needs to be applied (but this is still under
investigation) [24].
The most common functional test used in everyday
clinical practice in diabetic patients is VA determina-
tion. VA is still considered the gold standard in clinical
practice of vision testing, but it does not adequately
reflect functional vision. Functional vision describes
the impact of sight on quality of life. This parameter
better represents the patient’s point of view [10]. The
most widely adopted test for VA assessment is the
Snellen chart, although it has well-documented limits
and does not allow for direct comparison of data
obtained from different studies [25]. Therefore, new
and more standardized charts with logMAR progres-
sion have been designed and introduced into clinical
practice (and adopted for the Early Treatment Diabetic
Retinopathy Study (ETDRS chart) in order to create
more reliable and universal language in clinical trials,
when measuring VA [26].
Recently, the Diabetic Retinopathy Clinical Research
Network reported only modest correlation between
VA and OCT-measured center point thickness in
diabetic patients. They also found a modest correlation
between changes in retinal thickening and VA after
focal laser treatment for DME, suggesting that OCT
measurement alone may not be a good surrogate for
VA as a primary outcome in studies of DME [22].
Therefore other functional tests need to be evaluated
and compared with OCT in order to better understand
DME evolution and treatment outcomes. Besides VA,
other functional tests have been used to evaluate
functional alterations in diabetic patients. These
include both psychophysical tests [such as: color
vision, contrast sensitivity, dark adaptation (nyctom-
etry), perimetry, and more recently microperimetry] or
electrophysiological tests (multifocal electroretinog-
raphy, visual-evoked potentials). Among these tests,
just microperimetry provides exact, point-by-point
correlation between morphology and function. Recently,
microperimetry has gained increasing importance in
evaluation of functional impairment in diabetic
patients. Microperimetry, or fundus perimetry, is a
functional technique which quantifies macular sensi-
tivity, exactly correlating it to fundus characteristics,
and determines retinal fixation characteristics [10]. It
also allows for automatic and precise examination of
the same retinal points during follow-up, irrespective
of fixation changes [10]. In DME, a significant inverse
correlation between macular thickness and macular
sensitivity has been documented using microperime-
try (Fig. 1) [27–30]. Vujosevic et al. [27] reported a
significant inverse relationship between retinal
sensitivity and normalized thicknesses, with a decay
of 0.83 dB (p \ 0.0001) for every 10 % of deviation
of retinal thickness from the normal measurements
obtained with OCT. Therefore, microperimetry seems
to represent a better functional test than best corrected
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VA in quantifying visual function in diabetics, poten-
tially adding a functional measure that may supple-
ment the predictive value of OCT and VA [27].
Moreover, microperimetry allows for determination of
fixation location (central, relatively eccentric, and
eccentric) and stability (stable, relatively unstable,
and unstable). Published data about fixation charac-
teristics in DME eyes is quite contrasting, mostly due
to the differences in examined populations, espe-
cially differences in DME duration [29, 31, 32]. Kube
et al. [29] found decreased fixation stability in
patients with DME using SLO microperimetry.
Carpineto et al. [32] found that all eyes with eccentric
or unstable fixation had cystoid DME. Vujosevic et al.
[31] reported, in a well-defined group of CSME eyes,
that location and stability of fixation were normal,
except when hard exudates were located in the fovea.
DME pattern (focal or diffuse) or OCT type of edema
(cystoid, sponge-like, SND) did not influence stabil-
ity or location of fixation [31]. Therefore, the only
parameter influencing fixation in DME patients is
the presence of subfoveal hard exudates. In these
cases, knowledge of fixation characteristics is funda-
mental in order to avoid complications due to the
photocoagulation of a newly developed fixation
area [31].
Recently a new non-invasive test, short wavelength
fundus autofluorescence (FAF), has been proposed for
the evaluation of DME (Fig. 2) [33–35].
FAF, which examines the metabolic activity of retinal
pigment epithelium and photoreceptors, has been more
extensively used in the evaluation of age-related macular
degeneration and inherited macular dystrophies, but little
is known about FAF alterations in DME and its
functional correlations. Pece et al. [34] described
different increased patterns of FAF (multicystic
increased, single cyst increased, and combined single-
and multicystic increased FAF) in patients with cystoid
DME that correlated positively with FA and OCT
findings. In a more detailed study, Vujosevic et al. [35]
described three different patterns of foveal FAF in DME
patients (normal FAF, single spot increased FAF, and
multiple spot increased FAF) and correlated it with
microperimetry and VA data. Vujosevic et al. [35] found
that foveal FAF increases in a large proportion (76.8 %)
of patients with CSME and that retinal sensitivity
decreases over areas with increased FAF. Therefore,
DME with an increased FAF pattern is, at least
functionally, more severe than DME with a normal
FAF pattern. Although the origin of increased FAF in
DME patients is still not completely known, activation of
microglial cells has been hypothesized [36].
Fig. 1 a Microperimetry, b fundus autofluorescence, c fluores-
cein angiography and d OCT images (line scan and retinal
thickness map) of a diabetic patient with central cystoid macular
edema. Microperimetry shows initial decrease in central retinal
sensitivity. Fundus autofluorescence shows spots of increased
autofluorescence corresponding to intraretinal cysts on fluores-
cein angiography and OCT
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FAF and microperimetry have been recently eval-
uated after laser photocoagulation in DME [37].
Vujosevic et al. [37] evaluated micropulse diode laser
treatment (MPDL) versus modified ETDRS laser
photocoagulation in patients with center-involving
DME. These authors found that macular sensitivity
determined by microperimetry stabilizes or improves
after MPDL tretament whereas macular sensitivity
significantly decreases after modified ETDRS treat-
ment. FAF showed no changes after MPDL treatment,
whereas definite laser spots were easily seen on FAF
images after modified ETDRS treatment [36]. There-
fore less-invasive treatment options, with same effi-
cacy as standard treatments should become more
widespread, as recently reported [37, 38].
Although huge progress has been made in the
evaluation and treatment of DME, we still face
outcome pitfalls and we cannot differentiate, at
baseline examination, responders from non-respond-
ers to any individual treatment. Therefore more
analytical structural and functional evaluation, as
reported in this paper, of diabetic patients is needed
in order to obtain more precise DME phenotyping.
Using this systematic and detailed diagnostic
approach a more customized and selective manage-
ment of diabetics affected by DME should be possible,
allowing for better functional results and prevention of
permanent visual loss.
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